Gary M. Owens Sells 21,000 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CEO Gary M. Owens sold 21,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the completion of the sale, the chief executive officer now directly owns 43,337 shares of the company’s stock, valued at $5,369,887.67. The trade was a 32.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Mesa Laboratories Price Performance

Shares of MLAB stock opened at $128.45 on Tuesday. The company has a quick ratio of 0.53, a current ratio of 0.71 and a debt-to-equity ratio of 0.61. Mesa Laboratories, Inc. has a 12-month low of $83.68 and a 12-month high of $155.12. The firm has a fifty day moving average of $137.85 and a 200-day moving average of $129.24. The firm has a market capitalization of $698.00 million, a price-to-earnings ratio of -2.78 and a beta of 0.82.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. On average, equities research analysts forecast that Mesa Laboratories, Inc. will post 8 earnings per share for the current year.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Friday, February 28th were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.50%. The ex-dividend date was Friday, February 28th. Mesa Laboratories’s dividend payout ratio (DPR) is presently -1.38%.

Institutional Investors Weigh In On Mesa Laboratories

Several large investors have recently made changes to their positions in the stock. Pacer Advisors Inc. boosted its stake in Mesa Laboratories by 4.3% in the 4th quarter. Pacer Advisors Inc. now owns 1,755 shares of the medical instruments supplier’s stock worth $231,000 after purchasing an additional 73 shares during the period. Berry Wealth Group LP grew its holdings in shares of Mesa Laboratories by 5.3% during the fourth quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier’s stock worth $219,000 after buying an additional 83 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Mesa Laboratories by 3.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,925 shares of the medical instruments supplier’s stock worth $386,000 after buying an additional 98 shares in the last quarter. FMR LLC raised its position in Mesa Laboratories by 34.1% in the 3rd quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock valued at $51,000 after buying an additional 100 shares during the last quarter. Finally, Los Angeles Capital Management LLC lifted its stake in Mesa Laboratories by 3.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 3,394 shares of the medical instruments supplier’s stock valued at $448,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 90.60% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.